There was more progression on the ground glass opacities (GGOs), consolidations and crazy-paving pattern with bilateral and multifocal distribution in the placebo group compared to LCLT, which suggest LCLT may provide some protection against COVID-19 pneumonia

Managing and Preventing Skin Reactions Management of mild injection site reactions typically involves conservative, supportive measures: Cold compress apply a clean, cool compress to the affected area for 1015 minutes to reduce inflammation and discomfort Topical emollients use fragrance-free moisturisers to soothe dry or irritated skin Avoid scratching this may worsen inflammation and increase infection risk Over-the-counter antihistamines oral antihistamines such as cetirizine or loratadine may help relieve itching (consult a pharmacist or GP before use) Preventive strategies to minimise injection site reactions include: Proper injection technique ensure the medication is administered subcutaneously (not intramuscularly) into appropriate sites (abdomen, thigh, or upper arm) Rotate injection sites avoid injecting into the same area repeatedly
:format(webp))
During the study, the study d A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before Intervention 1 Intervention 2 Not provided Anticipated Start Date Not provided Actual Start Date 2019-05-09 Anticipated Date of Last Follow-up 2021-03-05 Estimated Primary Completion Date Not provided Estimated Completion Date Not provided Actual Primary Completion Date 2019-12-12 Actual Completion Date 2020-01-17 Age Cohort Genders Accepts pregnant individuals Unspecified Accepts lactating individuals Unspecified Accepts healthy individuals No Inclusion Criteria: * Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent * Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening * HbA1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory * Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s): 1

GHKCu is a small peptide that naturally binds copper
BPC 157 (Body Protection Compound 157) is a synthetic peptide derived from a protective protein naturally found in human gastric juices